Header Logo

Connection

NICOLA HANANIA to Adult

Back to Details
This is a "connection" page, showing publications NICOLA HANANIA has written about Adult.
NICOLA HANANIA
Connection Strength
0.971
Adult
  1. Comparative effectiveness of inhaled fluticasone propionate/salmeterol and budesonide/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis. Respir Med. 2025 Aug-Sep; 245:108172.
    View in: PubMed
    Score: 0.054
  2. Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
    View in: PubMed
    Score: 0.048
  3. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. J Allergy Clin Immunol Pract. 2022 01; 10(1):222-228.
    View in: PubMed
    Score: 0.042
  4. Association of Triglyceride-Glucose Index and Lung Health: A Population-Based Study. Chest. 2021 09; 160(3):1026-1034.
    View in: PubMed
    Score: 0.040
  5. Determinants of lung function improvement with omalizumab in adults with allergic asthma. J Allergy Clin Immunol Pract. 2020 06; 8(6):2068-2070.
    View in: PubMed
    Score: 0.037
  6. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019 04; 143(4):1629-1633.e2.
    View in: PubMed
    Score: 0.035
  7. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018 02; 73(2):490-497.
    View in: PubMed
    Score: 0.032
  8. Factors associated with depressive symptoms in uncontrolled asthmatics. J Asthma. 2018 05; 55(5):555-560.
    View in: PubMed
    Score: 0.032
  9. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
    View in: PubMed
    Score: 0.029
  10. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug; 70(8):748-56.
    View in: PubMed
    Score: 0.027
  11. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15; 187(8):804-11.
    View in: PubMed
    Score: 0.023
  12. Effect of a primary care continuing education program on clinical practice of chronic obstructive pulmonary disease: translating theory into practice. Mayo Clin Proc. 2012 Sep; 87(9):862-70.
    View in: PubMed
    Score: 0.022
  13. The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
    View in: PubMed
    Score: 0.022
  14. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011 05 03; 154(9):573-82.
    View in: PubMed
    Score: 0.020
  15. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J. 2010 Oct; 36(4):963-5.
    View in: PubMed
    Score: 0.020
  16. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011 Mar 01; 183(5):604-11.
    View in: PubMed
    Score: 0.020
  17. Burden of COPD in a government health care system: a retrospective observational study using data from the US Veterans Affairs population. Int J Chron Obstruct Pulmon Dis. 2010 May 06; 5:125-32.
    View in: PubMed
    Score: 0.019
  18. Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med. 2010 Aug; 104(8):1160-70.
    View in: PubMed
    Score: 0.019
  19. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
    View in: PubMed
    Score: 0.018
  20. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008; 21(1):134-41.
    View in: PubMed
    Score: 0.016
  21. The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med. 2007 May; 101(5):1007-14.
    View in: PubMed
    Score: 0.015
  22. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025 Jun; 13(6):505-516.
    View in: PubMed
    Score: 0.013
  23. Asthma outcomes in a safety net hospital system: A comparative study to a national cohort. Respir Med. 2025 Apr-May; 240:108032.
    View in: PubMed
    Score: 0.013
  24. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025 Mar; 13(3):234-243.
    View in: PubMed
    Score: 0.013
  25. Association of Insulin Resistance With Radiographic Lung Abnormalities and Incident Lung Disease: The Framingham Offspring Study. Diabetes Care. 2025 Jan 01; 48(1):143-148.
    View in: PubMed
    Score: 0.013
  26. Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
    View in: PubMed
    Score: 0.013
  27. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. J Allergy Clin Immunol. 2004 Apr; 113(4):717-24.
    View in: PubMed
    Score: 0.012
  28. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
    View in: PubMed
    Score: 0.012
  29. Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023 11; 218:107414.
    View in: PubMed
    Score: 0.012
  30. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep; 124(3):834-43.
    View in: PubMed
    Score: 0.012
  31. Severe Monkeypox in Hospitalized Patients - United States, August 10-October 10, 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 04; 71(44):1412-1417.
    View in: PubMed
    Score: 0.011
  32. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020 09; 75(9):735-743.
    View in: PubMed
    Score: 0.010
  33. Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020 11; 125(5):565-576.e1.
    View in: PubMed
    Score: 0.010
  34. Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2020 09; 8(8):2630-2639.e6.
    View in: PubMed
    Score: 0.009
  35. The Hospital Readmissions Reduction Program and Readmissions for Chronic Obstructive Pulmonary Disease, 2006-2015. Ann Am Thorac Soc. 2020 04; 17(4):450-456.
    View in: PubMed
    Score: 0.009
  36. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1058-1068.
    View in: PubMed
    Score: 0.009
  37. Diagnosis and Management of Pulmonary Hypertension in Patients With CKD. Am J Kidney Dis. 2020 06; 75(6):935-945.
    View in: PubMed
    Score: 0.009
  38. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020 05; 75(5):1023-1042.
    View in: PubMed
    Score: 0.009
  39. Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018 Dec; 53:20-26.
    View in: PubMed
    Score: 0.008
  40. Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients. Chest. 1998 Sep; 114(3):752-6.
    View in: PubMed
    Score: 0.008
  41. Results of a Pulmonologist Survey Regarding Knowledge and Practices With Inhalation Devices for COPD. Respir Care. 2018 07; 63(7):840-848.
    View in: PubMed
    Score: 0.008
  42. Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2018 Mar - Apr; 6(2):633-643.e1.
    View in: PubMed
    Score: 0.008
  43. Trends in 30-day readmission rates after COPD hospitalization, 2006-2012. Respir Med. 2017 Sep; 130:92-97.
    View in: PubMed
    Score: 0.008
  44. Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. J Aerosol Med Pulm Drug Deliv. 2017 Aug; 30(4):256-266.
    View in: PubMed
    Score: 0.008
  45. Factors associated with emergency department dependence of patients with asthma. Chest. 1997 Feb; 111(2):290-5.
    View in: PubMed
    Score: 0.008
  46. Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. J Allergy Clin Immunol Pract. 2017 Jul - Aug; 5(4):1025-1031.e2.
    View in: PubMed
    Score: 0.008
  47. Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.
    View in: PubMed
    Score: 0.007
  48. Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort. Chest. 2016 Apr; 149(4):916-26.
    View in: PubMed
    Score: 0.007
  49. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol. 1995 Nov; 96(5 Pt 1):571-9.
    View in: PubMed
    Score: 0.007
  50. Health-care utilization after near-fatal asthma. Chest. 1995 Jun; 107(6):1564-9.
    View in: PubMed
    Score: 0.007
  51. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
    View in: PubMed
    Score: 0.007
  52. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma. J Biol Chem. 2014 May 02; 289(18):12623-32.
    View in: PubMed
    Score: 0.006
  53. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec; 132(6):1295-302.
    View in: PubMed
    Score: 0.006
  54. Tuberculosis presenting with generalized lymphadenopathy, pulmonary infiltrates, and bone destruction in a young man. Arch Intern Med. 1993 May 24; 153(10):1265-7.
    View in: PubMed
    Score: 0.006
  55. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92.
    View in: PubMed
    Score: 0.006
  56. Comparative effectiveness of noninvasive ventilation vs invasive mechanical ventilation in chronic obstructive pulmonary disease patients with acute respiratory failure. J Hosp Med. 2013 Apr; 8(4):165-72.
    View in: PubMed
    Score: 0.006
  57. Age-related differences in asthma outcomes in the United States, 1988-2006. Ann Allergy Asthma Immunol. 2013 Apr; 110(4):240-6, 246.e1.
    View in: PubMed
    Score: 0.006
  58. Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012 Aug 23; 10:100.
    View in: PubMed
    Score: 0.006
  59. Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. J Allergy Clin Immunol. 2012 May; 129(5):1252-1258.e1.
    View in: PubMed
    Score: 0.005
  60. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22; 365(12):1088-98.
    View in: PubMed
    Score: 0.005
  61. Racial differences in quality of life in patients with COPD. Chest. 2011 Nov; 140(5):1169-1176.
    View in: PubMed
    Score: 0.005
  62. Resting energy expenditure and protein turnover are increased in patients with severe chronic obstructive pulmonary disease. Metabolism. 2011 Oct; 60(10):1449-55.
    View in: PubMed
    Score: 0.005
  63. Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc. 2011 May; 86(5):375-81.
    View in: PubMed
    Score: 0.005
  64. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011 Jul; 107(1):65-70.
    View in: PubMed
    Score: 0.005
  65. Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2010 Feb 18; 5:1-10.
    View in: PubMed
    Score: 0.005
  66. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol. 2006 Dec; 118(6):1226-33.
    View in: PubMed
    Score: 0.004
  67. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 2006 May; 24(3):259-67.
    View in: PubMed
    Score: 0.004
  68. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther. 2005 May; 27(5):531-42.
    View in: PubMed
    Score: 0.003
  69. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma. 2002 Feb; 43(2):423-6.
    View in: PubMed
    Score: 0.003
  70. The accuracy of a handheld portable spirometer. Chest. 1996 Jan; 109(1):152-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.